Published on 23/12/2025

Track and Trace Data Management and Retention Requirements

In the global pharmaceutical industry, regulatory compliance plays a crucial role in ensuring patient safety and product integrity. The demands for DSCSA FMD serialization compliance services are rising thanks to the introduction of stringent regulations like the Drug Supply Chain Security Act (DSCSA) in the United States and the Falsified Medicines Directive (FMD) in the European Union. This guide aims to empower pharmaceutical professionals focused on regulatory affairs, quality assurance (QA), and compliance with a clear understanding of the track and trace data management and retention requirements associated with these regulations.

Understanding the Legal Framework for Serialization

The requirements for track and trace systems in the pharmaceutical supply chain are driven by the need to enhance security and reduce the risk of counterfeit medicines. In the U.S., the Drug Supply Chain Security Act (DSCSA) was enacted in 2013, mandating serialization of prescription drugs and a standardized track-and-trace system to improve pharmaceutical supply chain security.

Similarly, the EU introduced the Falsified Medicines Directive (FMD) in 2011 to combat counterfeit pharmaceuticals and mandated the serialization of prescription medicines. The intent is to ensure that only authorized products reach patients by requiring verification at every level of the supply chain.

During the implementation of these regulations, entities need to be aware of the specific serialization and data management requirements mandated by the respective regulatory authorities. Let’s look at the key components in these frameworks.

Step 1: Identifying Serialization Requirements

The primary goal of serialization is to provide a unique identifier for each pharmaceutical product. In the case of the DSCSA, manufacturers must assign unique identifiers to each package and homogenous case of their products. Similarly, the FMD establishes identical requirements for EU-based manufacturers.

• DSCSA Requirements: The DSCSA requires that the unique identifier includes the National Drug Code (NDC), serial number, lot number, and expiration date.
• FMD Requirements: The FMD requires the unique identifier, a batch number, and an expiry date for each medicinal product.
• Data Storage: The serialized data must be securely stored and easily retrievable for inspections and audits.

Step 2: Understanding Data Management Protocols

Data management is crucial in ensuring that serialized information is automatically captured, stored, and exchanged between various stakeholders in the supply chain. Robust data management protocols must comply with globally recognized standards, including Good Distribution Practice (GDP).

Here are essential elements of effective data management:

• Data Collection: Ensure electronic systems are in place to capture data at each stage of the supply chain, from manufacture to distribution.
• Data Validation: Implement strong validation checks to ensure that the serialized data corresponds with the physical products.
• Data Sharing: Establish secure and efficient data-sharing agreements between trading partners to facilitate traceability of the drugs.

Step 3: Retention Requirements for Track and Trace Data

Both the DSCSA and FMD enforce specific data retention guidelines, aimed at maintaining comprehensive records for traceability and compliance inspections. It is critical that pharmaceutical companies adhere to the following retention timelines:

• DSCSA: Under DSCSA, companies must retain transaction information for at least six years following the date of each transaction.
• FMD: The FMD requires records to be retained for a minimum of five years.

Companies must also ensure that their systems are capable of archiving data adequately. This may include employing cloud solutions or dedicated servers to ensure data integrity and accessibility.

Step 4: Implementing Security Protocols

Data security in the context of serialized information management is essential to prevent unauthorized access and data breaches. Entities must establish stringent security protocols including:

• Access Control: Limit access to serialized data to authorized personnel only. Implement user authentication mechanisms such as multi-factor authentication.
• Data Encryption: Utilize encryption for data both in transit and at rest to safeguard sensitive information.
• System Integrity Checks: Regularly conduct audits and system checks to ensure that data integrity is maintained throughout its lifecycle.

Step 5: Training and Awareness

A skilled workforce is crucial in adhering to compliance requirements. Regular training sessions focusing on both DSCSA and FMD serialization mandates, data management practices, and security protocols must be enforced. This includes:

• Initial Training: Advise all employees on the importance of serialization and the regulations governing data management and retention.
• Continuous Education: Encourage ongoing learning through workshops and refresher courses pertaining to evolving regulations and technologies.
• Documentation of Training: Maintain documented records of employee training to demonstrate compliance during inspections.

Step 6: Monitoring and Compliance Audits

Continuous monitoring and conducting internal audits are vital for ensuring compliance with regulatory requirements. Pharmaceutical companies should consider the following best practices:

• Routine Audits: Set a schedule for regular internal audits of systems, processes, and compliance with serialization requirements.
• Corrective Actions: Develop and implement corrective action plans in response to audit findings or compliance gaps.
• Compliance Reporting: Prepare detailed compliance reports for management and relevant regulatory bodies, ensuring transparency and accountability.

Step 7: Engaging with Regulatory Authorities

Maintaining an open line of communication with regulatory authorities enhances compliance efforts. Stay updated on regulatory changes or guidelines by regularly reviewing resources from EMA, MHRA, and other relevant authorities. Companies should also consider the following:

• Engagement Strategy: Develop and implement a proactive approach in engaging with regulatory bodies for updates and guidance on compliance.
• Feedback Mechanism: Establish a feedback mechanism to gather insights from regulatory bodies, which can be incorporated into compliance strategies.
• Public Submission: Be prepared to submit requested documentation or data demonstrating compliance whenever required.

Conclusion

In conclusion, compliance with track and trace data management and retention requirements is paramount for pharmaceutical companies operating under the scrutiny of both the DSCSA and FMD. By following the steps outlined in this guide, organizations can create a robust framework for managing serialized data that not only meets regulatory requirements but also enhances patient safety and confidence in the pharmaceutical supply chain.

For organizations looking to enhance their compliance efforts, investing in DSCSA FMD serialization compliance services can play a critical role in navigating complex regulatory landscapes and ensuring adherence to the highest standards of pharmaceutical distribution.